Skip to content

Projected Prognosis as a Predictor of Short-term Outcome After Treatment of Minor Musculoskeletal Injuries in the Emergency Department

Projected Prognosis as a Predictor of Short-term Outcome After Treatment of Minor Musculoskeletal Injuries in the Emergency Department: A Prospective Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04011917
Enrollment
432
Registered
2019-07-09
Start date
2019-08-15
Completion date
2019-11-15
Last updated
2020-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Musculoskeletal Diseases

Keywords

Minor Musculoskeletal Injuries, Emergency Department, Prediction outcome, Extended Scope Physiotherapists

Brief summary

This study describes the caseload treated by the extended scope physiotherapists(ESP) working in the emergency department at Slagelse Hospital. Patients treated by the ESP during a 3 month period will be included in this study. Furthermore we aim to assess if ESPs treating patients with minor musculoskeletal injuries in the ED can predict the short-term prognosis of recovery. The prediction is made at hospital discharge using a (-7/+7) numerical rating scale (-7=poor prognosis; 7=best prognosis).

Interventions

BEHAVIORALStandard care

Treatment by an extended scope physiotherapist following Standard Operating Procedures.

Sponsors

Bispebjerg Hospital
CollaboratorOTHER
Slagelse Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* 1 Treated by an ESP for a minor musculoskeletal injury in the emergency room * 2 Has an email address * 3 Signed informed consent form

Exclusion criteria

* 1 A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., not having access to the internet, cognitive impairments etc.) * 2 Under the influence of drugs or alcohol

Design outcomes

Primary

MeasureTime frameDescription
Transition ratings of global perceived effect1 month after dischargeUsing a transition questionnaire (TRANS-Q) the perceived effect of treatment will be measured by participants answering if their current health status is unchanged, worse or better compared to their pre-injury status. unchanged equals a transition score of 0. If the participant answers worse, he/she is asked to rate the degree of worsening on a 7 point Likert scale, with corresponding scores ranging from -1 to -7. If the participant answers better, he/she is asked to rate the degree of improvement on a 7 point Likert scale, with corresponding scores ranging from 1 to 7. Thus the GPE score range from -7 (worsening) to 7 (improvement), with the mid-point - 0 - representing no change.

Secondary

MeasureTime frame
Patient Acceptable Symptom State1 month after discharge
EuroQoL questionnaire1 month after discharge

Other

MeasureTime frameDescription
VAS PainAt baseline and 1 month after dischargeThe VAS pain is a measure of pain intensity, which has been widely used in diverse adult populations. The scale is a unidimensional continuous scale comprised of a horizontal line, anchored by 2 verbal descriptors, one for each symptom extreme (0 no pain, 10 the worst imaginable pain).
Re-injury1 month after dischargeThe participants self-reported reinjury rate during the 1-month follow-up period will be recorded.
Analgesic use1 month after dischargeThe participants self-reported use of analgesics will be collected at the 1 month follow-up. Participants will be asked to note their use of analgesic drugs, within the week before the follow-up, only related to the treated injury in the emergency room.
Follow-up treatments1 month after dischargeThe participants self-reported use of follow-up visits with other allied health professionals will be recorded. All visits related to the treated injury during the 1-month follow-up period should be noted.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026